Emergent BioSolutions Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a $50 million option to its existing contract for the acquisition of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to commence this calendar year and be completed by April 2025.
This award follows a previously announced $30 million contract modification to supply CYFENDUS earlier this year. CYFENDUS, approved by the U.S. Food & Drug Administration in July 2023, is a two-dose anthrax vaccine indicated for post-exposure prophylaxis in individuals aged 18 through 65.
The procurement further strengthens U.S. anthrax preparedness, addressing anthrax as a Tier 1 biological threat due to its potential for bioterrorism and widespread public health impact. Emergent emphasizes its commitment to public health preparedness through its anthrax franchise, which also includes BioThrax and two treatments, Anthrasil and raxibacumab.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.